Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stake Lowered by Woodline Partners LP

Woodline Partners LP trimmed its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 0.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 1,044,610 shares of the company’s stock after selling 2,943 shares during the quarter. Woodline Partners LP’s holdings in Teva Pharmaceutical Industries were worth $23,023,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC increased its position in Teva Pharmaceutical Industries by 30.7% in the 4th quarter. FMR LLC now owns 81,983,231 shares of the company’s stock worth $1,806,910,000 after purchasing an additional 19,242,468 shares during the last quarter. Duquesne Family Office LLC increased its holdings in Teva Pharmaceutical Industries by 530.1% in the fourth quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company’s stock worth $198,303,000 after buying an additional 7,569,450 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd increased its holdings in Teva Pharmaceutical Industries by 12.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock worth $859,935,000 after buying an additional 4,418,961 shares during the last quarter. Todd Asset Management LLC bought a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $58,243,000. Finally, Marshall Wace LLP lifted its stake in Teva Pharmaceutical Industries by 87.8% in the fourth quarter. Marshall Wace LLP now owns 5,155,402 shares of the company’s stock valued at $113,625,000 after acquiring an additional 2,410,420 shares during the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Barclays decreased their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research report on Monday, April 28th. Bank of America raised their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Finally, StockNews.com raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, April 23rd. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $24.43.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $16.75 on Wednesday. Teva Pharmaceutical Industries Limited has a 12 month low of $12.47 and a 12 month high of $22.80. The company has a market cap of $18.99 billion, a P/E ratio of -11.55, a P/E/G ratio of 1.44 and a beta of 0.62. The business’s 50 day moving average is $15.36 and its two-hundred day moving average is $17.39. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. The business had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the company earned $0.48 earnings per share. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.